Photo from Yüksel Ürün/X
Dec 10, 2023, 16:59
Yüksel Ürün: MFS continues to be a reliable predictor for overall survival
Yüksel Ürün, Medical Oncologist at Ankara University, shared on X:
“With better access to docetaxel and other treatments for advanced prostate cancer, MFS continues to be a reliable predictor for overall survival. This reinforces MFS’s role as the main outcome for current adjuvant trials in localized prostate cancer, impacting future trial designs.”
For more details click here.
Source: Yüksel Ürün/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 16, 2024, 18:42
Nov 16, 2024, 17:57
Nov 16, 2024, 17:17
Nov 16, 2024, 16:54
Nov 16, 2024, 16:45
Nov 16, 2024, 16:41
Nov 16, 2024, 16:37